APNICAF 20MG INJECTION 3ML belongs to a group of medicines known as methylxanthines. It is used to treat apnea of premature newborns. Apnea is a condition in which breathing is interrupted, causing abnormal heart rate and oxygen saturation changes. It is a common occurrence, particularly in premature infants.

APNICAF 20MG INJECTION 3ML contains 'Caffeine Citrate', which belongs to the central nervous system (CNS) stimulants class. This medicine stimulates the respiratory centre, sensitising it to hypercapnia. Thereby, APNICAF 20MG INJECTION 3ML effectively regulates the mean respiratory rate and tidal volume, improves pulmonary blood flow, and enhances the breathing pattern.

A paediatrician or healthcare professional will administer APNICAF 20MG INJECTION 3ML in a hospital setting. APNICAF 20MG INJECTION 3ML can cause side effects like a fast heartbeat, irregular heartbeat, and increased blood sugar levels. These side effects are not prevalent and vary from person to person. Consult your doctor if these symptoms continue or worsen.

Inform your doctor about the complete medical history of your infant. If you are nursing your infant and are being treated with this medication, avoid drinking coffee or using any other caffeine-containing products since caffeine passes into breast milk. This medication should be used with caution in infants with impaired hepatic or renal function. Before adjusting the dose, your doctor may assess your child's baseline serum caffeine levels if they were born to a mother who consumes caffeine.

APNICAF 20MG INJECTION 3ML will be administered by a healthcare professional. Hence, do not self-administer to your newborn.

Inform your doctor about your infant's medical history. If you are breastfeeding and your infant is being treated with this medication, avoid drinking coffee or using any other caffeine-containing products since caffeine passes into breast milk. APNICAF 20MG INJECTION 3ML should only be used in a neonatal intensive care unit where adequate patient surveillance and monitoring facilities are available. Treatment should begin under the supervision of a neonatologist with experience in neonatal intensive care. This medication should be used with caution in infants with impaired liver or kidney function.